scholarly journals The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants

2009 ◽  
pp. 693 ◽  
Author(s):  
Andrew Blann
Keyword(s):  
Venous Thromboembolism ◽  
New Anticoagulants ◽  
Prevention And Treatment

scholarly journals Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients

2013 ◽  
pp. 207 ◽  
Author(s):  
Antonio Gómez-Outes ◽  
Suárez-Gea ◽  
Lecumberri ◽  
Ana Isabel Terleira-Fernández ◽  
Emilio Vargas-Castrillón ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Potential Role ◽  
New Anticoagulants ◽  
Prevention And Treatment

scholarly journals Update on Rivaroxaban

2010 ◽  
Vol 3 ◽  
pp. CMBD.S5101
Author(s):  
Osama Moussa ◽  
Dipankar Chattopadhyay ◽  
Vish Bhattacharya
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Dose Adjustment ◽  
Coagulation Cascade ◽  
Regular Monitoring ◽  
New Anticoagulants ◽  
Frequent Dose ◽  
Prevention And Treatment ◽  
Advanced Stages ◽  
Specific Factors

Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to offer safe anticoagulation without the need for regular monitoring and frequent dose adjustment. Some of these newer drugs are in the advanced stages of clinical trials or have already completed them and thereby aim to provide more options in the management of thromboembolism. In the present review we discuss the currently available evidence supporting the use of these new anticoagulants, in particular rivaroxaban.

scholarly journals New anticoagulants in the prevention and treatment of venous thromboembolism

2011 ◽  
Vol 152 (25) ◽  
pp. 983-992 ◽  
Author(s):  
Mátyás Keltai ◽  
Katalin Keltai
Keyword(s):  
Venous Thromboembolism ◽  
Treatment Options ◽  
Factor Xa ◽  
Bleeding Risk ◽  
Current Treatment ◽  
Thrombin Inhibitors ◽  
Major Surgery ◽  
Direct Thrombin Inhibitors ◽  
New Anticoagulants ◽  
Prevention And Treatment

Clinical data on the risk factors, incidence, consequences and current treatment options of venous thromboembolism are reviewed. Current guidelines advise anticoagulant treatment for a few weeks or months in immobilized patients treated in hospital, and after major surgery. The initial treatment is based on heparin, followed by vitamin K antagonist treatment. Recently a number of new, partially orally administered medications have undergone clinical investigations and based on the results three of them were also registered for the prevention and treatment of venous thromboembolism. Direct thrombin inhibitors, direct and indirect Factor Xa inhibitors exhibited proven non-inferiority or superiority compared with traditional treatment options. The superior efficacy or non-inferiority was not accompanied with an increase in the bleeding risk. Results of the most important clinical trials are reviewed. Based on these results, prevention and treatment of venous thromboembolism will change substantially in the next future. Orv. Hetil., 2011, 152, 983–992.

scholarly journals Prevention and treatment of venous thromboembolism in patients with cancer

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 312-317 ◽  
Author(s):  
Agnes Y.Y. Lee
Keyword(s):  
Venous Thromboembolism ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Hospital Setting ◽  
Chemotherapeutic Agents ◽  
Ambulatory Setting ◽  
Individual Risk ◽  
Patients With Cancer ◽  
Gastrointestinal Problems ◽  
Prevention And Treatment

Abstract Robust evidence remains scarce in guiding best practice in the prevention and treatment of venous thromboembolism in patients living with cancer. Recommendations from major consensus guidelines are largely based on extrapolated data from trials performed mostly in noncancer patients, observational studies and registries, studies using surrogate outcomes, and underpowered randomized controlled trials. Nonetheless, a personalized approach based on individual risk assessment is uniformly recommended for inpatient and outpatient thromboprophylaxis and there is consensus that anticoagulant prophylaxis is warranted in selected patients with a high risk of thrombosis. Prediction tools for estimating the risk of thrombosis in the hospital setting have not been validated, but the use of prophylaxis in the ambulatory setting in those with a high Khorana score is under active investigation. Symptomatic and incidental thrombosis should be treated with anticoagulant therapy, but little is known about the optimal duration. Pharmacologic options for prophylaxis and treatment are still restricted to unfractionated heparin, low molecular weight heparin, and vitamin K antagonists because there is currently insufficient evidence to support the use of target-specific, non-vitamin K-antagonist oral anticoagulants. Although these agents offer practical advantages over traditional anticoagulants, potential drug interaction with chemotherapeutic agents, gastrointestinal problems, hepatic and renal impairment, and the lack of rapid reversal agents are important limitations that may reduce the efficacy and safety of these drugs in patients with active cancer. Clinicians and patients are encouraged to participate in clinical trials to advance the care of patients with cancer-associated thrombosis.

Venous Thrombosis and SARS-CoV-2

2021 ◽  
Author(s):  
Monika Zdanyte ◽  
Dominik Rath ◽  
Meinrad Gawaz ◽  
Tobias Geisler
Keyword(s):  
Intensive Care Unit ◽  
Pulmonary Embolism ◽  
Intensive Care ◽  
Venous Thromboembolism ◽  
Vascular Endothelium ◽  
Arterial Thrombosis ◽  
Review Article ◽  
Prevention And Treatment ◽  
All Cause Mortality ◽  
Thrombotic Complications

AbstractSARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is associated with high risk of venous and arterial thrombosis. Thrombotic complications, especially pulmonary embolism, lead to increased all-cause mortality in both intensive care unit and noncritically ill patients. Damage and activation of vascular endothelium, platelet activation, followed by thrombotic and fibrinolytic imbalance as well as hypercoagulability are the key pathomechanisms in immunothrombosis leading to a significant increase in thromboembolism in coronavirus disease 2019 (COVID-19) compared with other acute illnesses. In this review article, we discuss the incidence and prognosis, diagnosis, prevention, and treatment of venous thromboembolism in patients with COVID-19 disease, based on clinical experience and research available to date.

Sign in / Sign up

Export Citation Format

Share Document